Loading company…
Sorrect Sequence develops gene editing therapies for genetic, metabolic, and cardiovascular diseases.
Sorrect Sequence develops gene editing therapies, including its Translational Gene Editor tBE platform and CS-101 injectable drug. Its work targets genetic, metabolic, and cardiovascular diseases. Founded in 2020, it is based in Shanghai, with R&D and manufacturing centers there and a clinical registration and operations center in Beijing. It raised over CNY 100 million in Series A+ funding in August 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in